MDRX, US01988P1084

Veradigm stock falls 10 percent in OTC trading

Published on 10/05/2026 at 16:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Veradigm stock was at USD 4.50 on October 5, 2026, while the 2025 revenue outlook stood at USD 584 million to USD 589 million. A USD 8.00 analyst target adds a separate valuation marker.

MDRX, US01988P1084, Illustration mit AI erstellt.

Veradigm (ISIN US01988P1084) stock was trading at USD 4.50 on the OTC Expert Market on October 5, 2026, at 9:30 a.m. ET, down 10 percent from the prior close of USD 5.00. The decline puts the health information services company back in front of investors as its turnaround plan competes with the need to restore regular SEC reporting.

Turnaround plan sets the agenda

At investor conferences on September 15 and September 16, 2026, Veradigm presented a strategy built around resetting operations, recovering customer momentum and reigniting growth, according to The Globe and Mail. The plan covers provider, payer and life sciences activities and follows customer retention challenges that management linked to a flat revenue period since 2022.

The same report said Veradigm expected 2025 revenue of USD 584 million to USD 589 million. It also reported USD 75 million of debt at the end of 2025, giving investors two balance-sheet figures to weigh against the companys planned investment in products, customer experience and artificial intelligence.

Health data creates expansion room

Veradigm serves 20,000 independent medical practices and sees USD 350 million of white space in revenue cycle services, including a potential USD 100 million incremental revenue opportunity within its existing customer base, according to Quartr. That opportunity is material relative to the 2025 revenue outlook, but converting installed-base potential into recurring sales remains the central operating test.

The company also connects providers, payers and life sciences firms through a unified health network architecture, with electronic health records, practice management and revenue cycle tools at its core. Veradigm described artificial intelligence and real-world data products as growth tools at the September conference, rather than relying solely on market expansion.

Analyst target exceeds market price

The Globe and Mail reported on September 16, 2026, that the most recent analyst rating was Buy with a USD 8.00 price target. The target lies 77.8 percent above the USD 4.50 market price, creating a wide gap that reflects both the potential of the turnaround and the execution risk attached to it.

Veradigm stock trades below USD 5

Veradigm stock was last at USD 4.50 on the OTC Expert Market on October 5, 2026, at 9:30 a.m. ET. The session volume was 151 shares, while the 52-week range was USD 3 to USD 6 and market capitalization was USD 764.2 million on the same date.